Rachael Natrajan

Resistance to therapy caused by intragenic deletion in BRCA2

Stacey L. Edwards, Rachel Brough, Christopher J. Lord et al. · Nature · 2008 · 979 citations

Intragenic Deletion, Oncogenic Agent, Pathology +4

Complex landscapes of somatic rearrangement in human breast cancer genomes

Philip J. Stephens, David J. McBride, Meng‐Lay Lin et al. · Nature · 2009 · 838 citations

Chromatin, Complex Landscapes, Somatic Variant +11

BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells

Gemma Molyneux, Felipe C. Geyer, Fiona‐Ann Magnay et al. · Cell stem cell · 2010 · 800 citations · Full text

Lineage Plasticity, Breast Oncology, Developmental Biology +8

<i>FGFR1</i> Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

Nicholas C. Turner, Alex Pearson, Rachel Sharpe et al. · Cancer Research · 2010 · 712 citations · Full text

Endocrine Oncology, Breast Oncology, Endocrine-related Cancer +14

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

Nicholas C. Turner, Maryou B. Lambros, Hugo M. Horlings et al. · Oncogene · 2010 · 405 citations · Full text

Breast Oncology, Functional Genomics, Potential Therapeutic Targets +11